Quarterly report pursuant to Section 13 or 15(d)

Revenue (Details)

v3.21.2
Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Apr. 01, 2021
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Disaggregation of Revenue [Line Items]          
Total revenue   $ 3,355 $ 1,338 $ 3,829 $ 4,092
Period before expiration to be considered as inventory       6 months  
Millipred | Teva          
Disaggregation of Revenue [Line Items]          
Percent of net profit for installment payments 50.00%        
Installment payment $ 500        
Product Revenue          
Disaggregation of Revenue [Line Items]          
Total revenue   2,730 1,338 $ 3,204 4,092
License revenue          
Disaggregation of Revenue [Line Items]          
Total revenue   $ 625 $ 0 $ 625 $ 0
Sales Revenue | Customer Concentration Risk | Major Customer Number One          
Disaggregation of Revenue [Line Items]          
Concentration risk percentage   62.00%   64.00%  
Sales Revenue | Customer Concentration Risk | Major Customer Number Two          
Disaggregation of Revenue [Line Items]          
Concentration risk percentage   17.00%   16.00%  
Sales Revenue | Customer Concentration Risk | Major Customer Number Three          
Disaggregation of Revenue [Line Items]          
Concentration risk percentage   20.00%   19.00%